Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
The stock's fall snapped a four-day winning streak.
RBC quantitative analyst makes eight changes to his top 40 stock picks list
RBC Capital Markets analyst Bish Koziol made eight changes to his quantitatively driven top 40 list of stock picks. Maple ...
Promising Biotech Stocks To Follow Today – February 05th
AbbVie, Danaher, Vertex Pharmaceuticals, Cencora, GSK, Thermo Fisher Scientific, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks ...
CenExel Celebrates FDA Approval of JOURNAVX(TM), a Groundbreaking Non-Opioid Pain Treatment
SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...
STAT16h
Crisis in CRISPR world, RFK Jr.’s promises, and a novel non-opioid pain drug
Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...
sicklecellanemianews20h
SCD gene-editing therapy Casgevy now being offered at CHLA
With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.
pharmaphorum2h
Will 2025 be the year the pharmaceutical industry finds its feet?
Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...
BioPharma Dive18h
Bristol Myers, bracing for key patent losses, deepens cost-cutting plan
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...